Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month High – Should You Buy?

Shares of Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $27.19 and last traded at $26.61, with a volume of 52586 shares. The stock had previously closed at $26.29.

Chugai Pharmaceutical Stock Up 1.2 %

The stock’s 50-day moving average price is $22.30 and its 200-day moving average price is $22.90. The company has a market capitalization of $87.57 billion, a price-to-earnings ratio of 34.56 and a beta of 0.81.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. On average, equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.